Free Trial

Cybin (OTCMKTS:CYBN) Trading Down 16.6% - Here's What Happened

Cybin logo with Medical background

Key Points

  • Cybin Inc. experienced a significant decline in share price, trading down 16.6%, closing at $6.24 after a low of $6.15 during Tuesday's trading.
  • The company's trading volume surged to 1,751,672 shares, an increase of 427% compared to the average session volume.
  • Cybin is a clinical-stage biopharmaceutical company focusing on developing psychedelic-based therapeutics, with several compounds currently in various stages of clinical trials.
  • MarketBeat previews the top five stocks to own by October 1st.

Cybin Inc. (OTCMKTS:CYBN - Get Free Report)'s share price traded down 16.6% during trading on Tuesday . The company traded as low as $6.15 and last traded at $6.24. 1,751,672 shares were traded during mid-day trading, an increase of 427% from the average session volume of 332,177 shares. The stock had previously closed at $7.48.

Cybin Price Performance

The business has a 50 day moving average price of $7.61 and a 200 day moving average price of $7.45. The firm has a market capitalization of $147.20 million, a P/E ratio of -32.84 and a beta of 0.68.

Cybin Company Profile

(Get Free Report)

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Cybin Right Now?

Before you consider Cybin, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cybin wasn't on the list.

While Cybin currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

September Rate Cuts: 3 Stocks Set to Benefit Most
Markets Are Sliding: Where to Find Opportunity
5 Hot Stocks to Buy Now: September’s Top Picks With Major Momentum

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines